8-K: ImmunityBio Reports Strong Q1 2026 Revenue Growth

ImmunityBio announced record Q1 2026 results with net product revenue soaring to $44.2 million, a nearly 2.7x increase year-over-year, driven by strong ANKTIVA sales and expanding market approvals.

Summary

• ImmunityBio reported record net product revenue of $44.2 million for the first quarter of 2026, a 168% increase compared to Q1 2025 and a 15% increase from Q4 2025.
• The company's cash, cash equivalents, and marketable securities stood at $380.9 million as of March 31, 2026, an increase from $242.8 million at the end of 2025.
• ANKTIVA unit sales volume increased by 168% in Q1 2026 compared to Q1 2025.
• ANKTIVA has received approval or authorization in five regulatory jurisdictions, covering approximately 34 countries, including its first approval in Asia.
• The NCCN Clinical Practice Guidelines now include ANKTIVA plus BCG for specific categories of BCG-unresponsive NMIBC patients.
• The pivotal BCG-Nave CIS trial is fully enrolled, with an sBLA submission on track for 2026.
• Research and Development expenses increased to $68.0 million in Q1 2026 from $48.2 million in Q1 2025.
• Selling, General, and Administrative expenses increased to $45.8 million in Q1 2026 from $32.7 million in Q1 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive report due to record revenue growth, expanding market approvals, and a strengthened cash position, despite increased operating expenses and net loss.

Positives

• Net product revenue reached a record $44.2 million in Q1 2026, marking a 168% year-over-year increase and continuing a trend of quarterly growth since ANKTIVA's commercial launch.
• The company's cash position strengthened significantly, reaching $380.9 million as of March 31, 2026, up from $242.8 million at the end of 2025.
• ANKTIVA unit sales volume saw a substantial 168% increase in Q1 2026 compared to the prior year's first quarter.
• ANKTIVA's regulatory approvals have expanded to five jurisdictions, encompassing approximately 34 countries, including a significant first approval in Asia.
• The NCCN guidelines now recommend ANKTIVA plus BCG for certain BCG-unresponsive NMIBC patient populations, indicating growing clinical acceptance.
• The pivotal BCG-Nave CIS trial has completed enrollment, supporting a planned sBLA submission in 2026.
• Commercial availability of ANKTIVA has been achieved within two months of a MENA partnership announcement.

Negatives

• Net loss attributable to common stockholders was $632.8 million in Q1 2026, a significant increase from $129.6 million in Q1 2025.
• Research and Development expenses rose by $19.8 million to $68.0 million in Q1 2026 compared to Q1 2025.
• Selling, General, and Administrative expenses increased by $13.1 million to $45.8 million in Q1 2026 compared to Q1 2025.
• Other expense, net, increased dramatically to $563.0 million in Q1 2026 from $65.5 million in Q1 2025, primarily due to non-cash changes in the fair value of liabilities.
• Adjusted Net Loss (non-GAAP) increased slightly to $86.2 million in Q1 2026 from $82.7 million in Q1 2025.

Risks

• Potential delays in product availability and regulatory approvals.
• The ability to fund ongoing and anticipated clinical trials.
• The success of continued preclinical and clinical development, patient enrollment, and planned regulatory submissions.
• Potential product shortages or manufacturing disruptions impacting availability and timing.
• The ability to successfully commercialize approved product and product candidates.
• The ability to scale manufacturing and commercial supply operations.
• Risks and uncertainties regarding participation, enrollment, and potential results from clinical trials.
• Whether clinical trial data will be accepted by regulatory agencies.

Future Outlook

The company anticipates a supplemental BLA submission in 2026 for its pivotal BCG-Nave CIS trial. Commercial availability is expanding beyond the U.S., with additional markets anticipated this year. Management expresses confidence in continued growth supported by a strong cash position and an experienced commercial organization.

Management Comments

• "We continue to see strong demand for ANKTIVA from both new prescribers and physicians expanding use across multiple eligible patients, including in the maintenance setting."
• "We have also made meaningful progress expanding market access beyond the U.S., with ANKTIVA now commercially available in Saudi Arabia and additional markets anticipated this year."
• "We are entering Q2 with a strong cash position, growing revenues, and a more experienced commercial organization positioned to support continued growth."
• "We are encouraged by the steady progress of our clinical programs and regulatory submissions across NMIBC and non-small cell lung cancer (NSCLC)."
• "The full enrollment of our pivotal BCG-nave NMIBC trial, with independent confirmation that no additional patients are required, supports our planned sBLA submission in 2026."
• "In parallel, recent NCCN guideline updates now include ANKTIVA plus BCG for patients with BCG-unresponsive papillary-only disease, reinforcing the growing clinical evidence supporting our approach across a broader spectrum of bladder cancer patients."
• "We are also advancing our NSCLC program in a randomized trial in patients who have progressed following prior checkpoint inhibitor therapy, an area of significant unmet need, alongside continued development of our cell therapy platforms, including CD19-targeted therapies in non-Hodgkin lymphoma and Waldenstrms macroglobulinemia, and PD-L1 t-haNK in glioblastoma."

Industry Context

StockSavvy.ai notes that ImmunityBio's strong revenue growth in Q1 2026, particularly with ANKTIVA, aligns with the broader trend in the oncology sector towards targeted immunotherapies and expanding market access for novel treatments. The inclusion in NCCN guidelines is a significant positive indicator for market adoption.

Comparison to Industry Standards

• While specific direct comparisons to competitors' Q1 2026 results are not provided in the filing, ImmunityBio's reported 168% year-over-year product revenue growth for ANKTIVA significantly outpaces the typical growth rates seen in established oncology drug markets, suggesting strong early-stage commercial traction.
• The company's cash position of $380.9 million is robust for a biotechnology company at this stage, providing runway for continued clinical development and commercialization efforts, which is a key benchmark for investor confidence in the sector.

Related Party Transactions

• Research and development expenses related to parties are noted.
• Selling, general and administrative expenses related to parties are noted.
• Non-cash changes in fair value of liabilities included a related-party convertible note.
• Interest expense related to a related-party convertible note is noted.

Stakeholder Impact

• Shareholders: Positive impact from strong revenue growth and increased cash position, potentially leading to increased valuation, but offset by a significant net loss.
• Employees: Continued investment in R&D and SG&A suggests ongoing operational expansion and potential for growth.
• Customers (Patients/Physicians): Increased availability and regulatory acceptance of ANKTIVA, including NCCN guideline inclusion, benefits patients and healthcare providers.
• Creditors: The strong cash position provides comfort regarding the company's ability to meet its financial obligations.

Next Steps

• On track for a supplemental BLA submission in 2026 for the pivotal BCG-Nave CIS trial.
• Continued expansion of ANKTIVA's commercial availability in additional international markets.
• Advancing the NSCLC program in a randomized trial.
• Continued development of cell therapy platforms, including CD19-targeted therapies and PD-L1 t-haNK.

Key Dates

Recommendation

The strong revenue growth and expanding market approvals for ANKTIVA are highly positive. However, the significant increase in net loss, driven by non-cash accounting adjustments and higher operating expenses, warrants a cautious approach. The company's substantial cash reserves provide a buffer, but continued investment in R&D and commercialization is necessary, making it a hold until profitability trends become clearer.

Keywords

ImmunityBio, ANKTIVA, NMIBC, Biotechnology, Oncology, Clinical Trials, Revenue Growth, Financial Results